Your Daily Pharmaceuticals Briefing

FDA Extends Review for AstraZeneca's Breast Cancer Drug Camizestrant

• The U.S. Food and Drug Administration (FDA) has extended its review period for AstraZeneca's camizestrant, an oral selective estrogen receptor degrader (SERD) for advanced breast cancer, to evaluate additional data. This decision follows a six-to-three vote by the FDA's Oncologic Drugs Advisory Committee (ODAC) in April 2026, which questioned whether the drug provided a clinically meaningful benefit based on the SERENA-6 Phase III trial, despite the trial showing a 56% reduction in the risk of disease progression or death when switching to camizestrant.

  AstrazenecaFiercebiotechOnclive

• AstraZeneca has submitted further analyses, including circulating tumor DNA (ctDNA) clearance data linked to longer-term efficacy outcomes, which are slated for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2. The FDA's request for more data highlights its rigorous scrutiny of novel treatment paradigms, particularly those involving treatment switches based on molecular markers rather than radiographic progression.

  AstrazenecaFiercebiotechOnclive

• In a separate development, the European Commission announced on May 28, 2026, that initial doses of favipiravir, an experimental antiviral, are being sent to France, Spain, and the Netherlands for the treatment of hantavirus, a rodent-borne illness. This action comes as the European Medicines Agency identified favipiravir as the most plausible candidate for use under clinical trial or compassionate use protocols, with the EU initiating emergency procurement for additional doses.

  Whtc

• Meanwhile, Tencent Healthcare President Alex Ng noted on May 28, 2026, that smaller biotech firms are adopting artificial intelligence (AI) more rapidly than larger pharmaceutical companies to enhance research and development efficiency. Industry forecasts suggest that leveraging AI in target discovery, molecule design, and clinical trial planning could halve early-stage development timelines and costs within the next three to five years.

  Whtc